Charles Schwab
ECYT

Charles Schwab’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Charles Schwab’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-337,671
Closed -$6M – 3156
2018
Q3 		$6M Buy
337,671
+198,971
+143% +$3.42M ﹤0.01% 1948
2018
Q2 		$1.92M Buy
138,700
+127,400
+1,127% +$1.51M ﹤0.01% 2394
2018
Q1 		$103K Hold
11,300
– – ﹤0.01% 3037
2017
Q4 		$49K Hold
11,300
– – ﹤0.01% 3051
2017
Q3 		$16K Sell
11,300
-54,451
-83% -$75.9K ﹤0.01% 3075
2017
Q2 		$99K Sell
65,751
-49,792
-43% -$107K ﹤0.01% 3080
2017
Q1 		$297K Buy
115,543
+5,472
+5% +$12.7K ﹤0.01% 2824
2016
Q4 		$281K Buy
110,071
+37,728
+52% +$108K ﹤0.01% 2867
2016
Q3 		$224K Sell
72,343
-39,890
-36% -$124K ﹤0.01% 2889
2016
Q2 		$361K Buy
112,233
+1,680
+2% +$6.16K ﹤0.01% 2713
2016
Q1 		$343K Buy
110,553
+2,040
+2% +$6.66K ﹤0.01% 2725
2015
Q4 		$436K Buy
108,513
+2,600
+2% +$12K ﹤0.01% 2705
2015
Q3 		$486K Sell
105,913
-37,229
-26% -$195K ﹤0.01% 2637
2015
Q2 		$743K Buy
143,142
+4,023
+3% +$24.1K ﹤0.01% 2537
2015
Q1 		$871K Buy
139,119
+47,170
+51% +$272K ﹤0.01% 2421
2014
Q4 		$579K Buy
91,949
+2,196
+2% +$13.4K ﹤0.01% 2563
2014
Q3 		$546K Buy
89,753
+1,729
+2% +$11.8K ﹤0.01% 2553
2014
Q2 		$581K Sell
88,024
-544
-0.6% -$6.13K ﹤0.01% 2560
2014
Q1 		$2.11M Buy
88,568
+11,840
+15% +$172K ﹤0.01% 1931
2013
Q4 		$821K Buy
76,728
+2,448
+3% +$27K ﹤0.01% 2362
2013
Q3 		$1.02M Buy
74,280
+3,298
+5% +$52.1K ﹤0.01% 2204
2013
Q2 		$979K Buy
+70,982
New +$957K ﹤0.01% 2175

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $830M AUM 21.8% 1-Year Est. Return

Charles Schwab's ECYT Position: Q4 2018 in Review

Charles Schwab sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 337,671 shares — an estimated $6M sold.

Charles Schwab first reported a position in ECYT in Q2 2013 and held it in 22 quarters. The position peaked at $6M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • Charles Schwab reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Charles Schwab sold 337,671 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $6M.
  • Charles Schwab first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 22 quarters.
  • Charles Schwab's Endocyte, Inc. Common Stock position peaked at $6M in Q3 2018.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Charles Schwab's 13F filing for Q4 2018, filed 14 Feb 2019.